Pneumococcal Infections clinical trials
The registry lists 298 studies for Pneumococcal Infections across more than 10 countries. 26 are recruiting or about to start. 221 of them are mainly about Pneumococcal Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its narrower condition Pneumonia, Pneumococcal too: 332 studies, 28 open.
Get an email when these change. Save the Pneumococcal Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Pfizer (60) · Merck Sharp & Dohme LLC (43) · GlaxoSmithKline (31) · Wyeth is now a wholly owned subsidiary of Pfizer (15) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · Sinovac Life Sciences Co., Ltd. (7) · CanSino Biologics Inc. (5) · Vaxcyte, Inc. (5)
What is being tested here
Drugs under test in Pneumococcal Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents · Phase 3 · Sanofi Pasteur, a Sanofi Company
- Feb 2027A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) · Phase 3 · CanSino Biologics Inc.
- Mar 2027A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age · Phase 3 · Vaxcyte, Inc.
- Mar 2027Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination · Phase 3 · Vaxcyte, Inc.
- Jun 2027A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults · Phase 3 · Pfizer
- Jun 2027Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age · Phase 3 · Sanofi
- Nov 2026In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn) · University Hospital, Geneva
- Nov 2026Randomized Controlled Trial Of Text Messages To Increase Pneumococcal Vaccination In Adults In Chile. · Pablo Tomás Valenzuela García
- Nov 2026Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) · CanSino Biologics Inc.
- Dec 2026Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV · Thomas Benfield
Who these studies take
Of the 21 Pneumococcal Infections studies recruiting now, 4 (19%) set no upper age limit and 15 (71%) stop at 75 or younger. 14 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 17 (81%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (19%) | 4 (19%) |
| 18 | 9 (43%) | 9 (43%) |
| 30 | 8 (38%) | 8 (38%) |
| 40 | 8 (38%) | 8 (38%) |
| 50 | 7 (33%) | 7 (33%) |
| 65 | 7 (33%) | 7 (33%) |
| 75 | 6 (29%) | 6 (29%) |
| 85 | 6 (29%) | 6 (29%) |
Across all 298 studies, recruiting or not: 66% stop at 75 or younger and 63% at 65; 55% take children; 1% are for women only and <1% for men only; 80% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Pneumococcal Infections studies take
Of 82 phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 13 mo7–16 · 27 studies | — | — |
| Phase 2 | 18 mo7–28 · 23 studies | — | — |
| Phase 3 | 13 mo9–23 · 82 studies | 13 mo9–23 · 81 studies | — |
| Phase 4 | 26 mo5–44 · 21 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 298. Browse all 298 → or search them.
- A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsRecruitingNCT07573462Phase 311 countries
- National, Non Interventional Study of Invasive Pneumococcal Disease in Children and NewbornsRecruitingNCT046645561 country
- Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and AdolescentsRecruitingNCT07660198Phase 34 countries
- Randomized Controlled Trial Of Text Messages To Increase Pneumococcal Vaccination In Adults In Chile.Enrolling by invitationNCT07659470Not applicable1 country
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.RecruitingNCT07629440Phase 33 countries
- A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to AdultsRecruitingNCT07794748Phase 31 country
- Opportunistic Pneumococcal Immunisation Trial in MALnutritionRecruitingNCT06817421Phase 41 country
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgeRecruitingNCT07348692Phase 34 countries
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)RecruitingNCT07300267Phase 11 country
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate VaccinesRecruitingNCT07135453Phase 41 country
- A Study to Evaluate 20vPnC in Healthy Chinese InfantsRecruitingNCT07754539Phase 31 country
- A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)Not yet recruitingNCT07648641
- Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)RecruitingNCT07600983Phase 1/21 country
- Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in AdultsRecruitingNCT06822907Phase 41 country
- Clinical Trial of PCV24 in Infants Aged 2-23 MonthsRecruitingNCT06800261Phase 11 country
- Clinical Trial of 13-Valent Pneumococcal Conjugate VaccineRecruitingNCT06617715Phase 31 country
- Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 YearsRecruitingNCT07300644Phase 21 country
- Serum Collection Study for Assay DevelopmentRecruitingNCT07205289Phase 11 country
- In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)RecruitingNCT069982511 country
- A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60Not yet recruitingNCT06970756Phase 11 country
- Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15RecruitingNCT06731374Phase 41 country
- A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 VaccineRecruitingNCT06608199Phase 31 country
- The Effect of AUDIT and Feedback on Pneumococcal Vaccination CoverageNot yet recruitingNCT05920499Not applicable1 country
- A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy PeopleRecruitingNCT06044077Phase 31 country
- Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial VirusNot yet recruitingNCT05017519
- Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIVRecruitingNCT04875819Phase 41 country
- A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsActive, not recruitingNCT06524414Phase 22 countries
- A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsCompletedNCT06182124Phase 1/21 country
- A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six MonthsActive, not recruitingNCT066221091 country
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeActive, not recruitingNCT07365826Phase 31 country
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and InfantActive, not recruitingNCT07023081Phase 11 country
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49CompletedNCT07284654Phase 31 country
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsCompletedNCT05412030Phase 22 countries
- Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in IndiaCompletedNCT00452790Phase 31 country
- Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedNCT06678620Phase 21 country
- Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 YearsCompletedNCT06675032Phase 11 country
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Active, not recruitingNCT07017777Phase 31 country
- Impact of HIV-1 and Aging on Mucosal Vaccine ResponsesActive, not recruitingNCT03729778Early Phase 11 country
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 MonthsCompletedNCT07333352Phase 21 country
- Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.CompletedNCT03873727Phase 21 country
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationActive, not recruitingNCT07425392Phase 31 country
- Surveillance of Invasive Pneumococcal Infections in Adults (Excluding Meningitis)CompletedNCT039836161 country
- A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In ChinaCompletedNCT01692886Phase 31 country
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy InfantsActive, not recruitingNCT06720038Phase 22 countries
- Systematic Search for Primary Immunodeficiency in Adults With InfectionsCompletedNCT02972281Not applicable1 country
- Clinical Trial of PCV24 in Adults Aged ≥18 YearsCompletedNCT07543198Phase 1/21 country
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)CompletedNCT06177912Phase 313 countries
- A Study to Learn About How a New Pneumococcal Vaccine Works in ChildrenCompletedNCT06531538Phase 22 countries
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)CompletedNCT05696080Phase 38 countries
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)CompletedNCT05569954Phase 311 countries